Related Experiment Video
Updated: Aug 14, 2026

07:34
Quantification of Circulating Pig-Specific DNA in the Blood of a Xenotransplantation Model
Published on: September 22, 2020
3.9K
Potential Infectious Complications in Pig Xenograft Donors and Recipients
Nicolas J Mueller1, Linda Scobie2
1Division of Infectious Diseases and Hospital Epidemiology, University Zurich, University Hospital Zurich, Zurich, Switzerland.
Summary
Preventing pig-to-human disease transmission is crucial for xenotransplantation success. Validated diagnostic tests are essential for screening donor animals and recipients to ensure safety in these life-saving procedures.
Area of Science:
- Xenotransplantation research
- Infectious disease control
- Veterinary virology
Background:
- Xenotransplantation, using animal organs in humans, faces challenges like disease transmission (xenozoonoses).
- Preclinical studies show pig viruses can transfer with transplanted organs, posing risks.
- Designated pathogen-free (DPF) donor animals are vital for pathogen elimination.
Purpose of the Study:
- To highlight the critical need for validated diagnostic regimens in xenotransplantation.
- To emphasize pathogen detection in donor animals and recipients for safety.
- To inform future xenotransplantation trials in Europe using existing data.
Main Methods:
- Review of preclinical and clinical xenotransplantation trial data.
- Analysis of pathogen detection challenges, particularly for latent viruses.
- Case study of pig-to-man cardiac transplantation involving porcine cytomegalovirus (PCMV) and porcine circovirus (PCV).
Main Results:
- Successful xenotransplantation outcomes are contingent on preventing xenozoonoses.
- PCMV and PCV were detected in a pig-to-man cardiac transplant, underscoring diagnostic needs.
- Validated, sensitive, and specific pathogen detection systems are required.
Conclusions:
- Rigorous diagnostic protocols are essential for safe xenotransplantation.
- Continuous improvement in pathogen detection is necessary for advancing xenotransplantation.
- Data from past trials must guide future diagnostic strategies for donor and recipient screening.

